期刊文献+

塞来昔布致急性胰腺炎 被引量:3

Acute pancreatitis due to celecoxib
原文传递
导出
摘要 1例43岁女性患者因肩周炎服用塞来昔布胶囊0.2g,2次/d,共服用2周。末次服药后2h上腹出现持续性钝痛,伴腹胀、恶心、呕吐。实验室检查示血清淀粉酶1822U/L,胰淀粉酶1529U/L,脂肪酶1410U/L,白细胞计数12.7×10^9/L,中性粒细胞0.74,淋巴细胞0.16。腹部超声检查和磁共振胰胆管造影示胰腺弥漫性增大、胰腺周围有液性渗出,诊断为急性胰腺炎。停用塞来昔布,禁食,给予营养支持和抑酶、抑酸、抗感染治疗13d,患者腹痛、腹胀消失,实验室检查示淀粉酶86U/L,胰淀粉酶48U/L,脂肪酶55U/L,白细胞计数7.2×10^9/L,中性粒细胞0.65,淋巴细胞0.32。胰腺CT示胰头、胰体和胰尾位于同一层面,形态及大小基本正常。 A 43-year-old woman with scapulohumeral periarthritis received celecoxib 0.2 mg twice daily for 2 weeks. She developed upper abdominal persistent dull pain, distension, nausea and vomiting two hours after the last administration. Laboratory tests showed the following values: serum amylase 1 822 U/L, amylopsin 1 529 U/L, lipase 1 410 U/L, white blood cell count 12.7 x 10^9/L, neutrophils 0.74, and lym phocytes 0. 16. Abdominal ultrasound examination and magnetic resonance cholangiopancreatography showed a diffusely enlarged pancreas and fluid exudation around pancreas. The patient was diagnosed as acute pancreatitis. Celecoxib was withdrawn. Thirteen days after the therapy with jejunitas, nutritional supporting, enzyme inhibition, acid suppression, and anti-infection, her symptoms of abdominal pain and distension were disappeared. Laboratory tests showed the following values : serum amylase 86 U/L, amylopsin 48 U/L, lipase 55 U/L, white blood cell count 7.2x 10^9/L, neutrophils 0.65, and lymphocytes 0.32. Abdominal CT showed caputpancreatis, corpora pancreatic, and pancreatic tail were located on the same level, the oancreatic shaoe and size were normal.
出处 《药物不良反应杂志》 CSCD 2014年第1期43-44,共2页 Adverse Drug Reactions Journal
关键词 塞来昔布 胰腺炎 Celecoxib Pancreatitis
  • 相关文献

参考文献11

  • 1孟敏,刘丽春,葛斌,汤浩,吴玉琼,徐杨.塞来昔布治疗类风湿性关节炎或骨关节炎疗效和安全性的Meta分析[J].中国循证医学杂志,2011,11(5):560-564. 被引量:40
  • 2董亚琳,罗秦英,姚鸿萍,郭永卿.塞来昔布的药理作用、药代动力学及临床评价[J].中国医院用药评价与分析,2002,2(5):271-276. 被引量:17
  • 3Mennecier D, Ceppa F, Sinayoko L, et al. Acute pancreatitis after treatment by celeeoxib [ J ]. Gastroenterol Clin Biol, 2007, 31(8-9 Pt 1) : 668-669.
  • 4Nind G, Selby W. Acute pancreatitis : a rare complication of cele- coxib[J]. Intern Med J, 2002, 32(12): 624-625.
  • 5Baciewicz AM, Sokos DR, King TJ. Acute pancreatitis associated with celecoxib[J]. Ann Intern Med, 2000, 132(8) : 680.
  • 6Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pan- creatitis and hepatitis : a case report [ J ]. Arch Intern Med, 2000, 160(4) : 553-554.
  • 7Godion J, Butanti RC, Peter W, et al. Acute drug-induced pancreatitis associated with eeleeoxib [ J ]. J Clin Rheumatoi, 1999, 5(5) :305.
  • 8Mahida YR, Beltinger J, Makh S, et al. Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyelooxygenase-1 and-2 [ J ]. Am J Physiol, 1997, 273 (6 Pt 1 ) : G1341-1348.
  • 9Zhang Y, Shaffer A, Portanova J, et al. Inhibition of cyclooxyge- nase-2 rapidly reverses inflammatory hyperalgesia and prosta- glandin E2 production [ J ]. J Pharmaeol Exp Ther, 1997, 283 (3) : 1069-1075.
  • 10孙春亮,黎介寿,朱维铭,汪俊军.前列腺素E_1对胰腺炎大鼠胰腺血流的影响[J].中国危重病急救医学,1998,10(3):154-157. 被引量:11

二级参考文献28

  • 1毕会民,胡胜,甘佩珍.塞来考昔对女性卵巢功能的影响[J].中国新药与临床杂志,2004,23(8):538-539. 被引量:1
  • 2Zhao SZ, Mcmillen JI, Markenson JA, et al. Evaluation of the functional status aspects of Health-Related Quality of Life of patients with osteoarthritis treated with Celecoxib. Pharmacotherapy, 1999, 19(11): 1269-1278.
  • 3Zhao SZ, FiechtnerJJ, Tindall EA, et al. Evaluation of Health- Related Quality of Life of rheumatoid arthritis patients treated with Celecoxib. Arthritis Care and Research, 2000, 13(2): 112-121.
  • 4Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of prospective randomized evaluation of Celecoxib inte- grated safety versus Ibuprofen or Naproxen (PRECISION), a cardio- vascular end point trial of nonsteroidal anti-inflammatory agents in patients with arthritis. Am Heart J, 2009, 157(4): 606-612.
  • 5Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of Celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulatio, 2008, 117(16): 2104-2113.
  • 6Lelorier J, Fitzsimon C, Keresteci M, et al. Drug utilization review of Celecoxib in Ontario. Rheumatology, 2003, 42(suppl 3): 11-16.
  • 7Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics, 2004, 22(2 Suppl 1): 1-12.
  • 8Nivsrkar M. Improvement in circulating superoxide dismutase levels: Role of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis biochemical and biophysical. Research Communications, 2000, 270(3): 714-716.
  • 9Niederberger E, Manderscheid C, Gr6sch S, et al. Effects of the se- lective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol, 2004, 68(2): 341-350.
  • 10Laine L, Connor LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or Coxib Use. Gastroenterology, 2003, 124(2): 288-292.

共引文献65

同被引文献34

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部